Developer docs
API playgroundTry for free, no card

Search company profiles

BIOPOA

Full company profile

uuid0003nma

Namestring
BIOPOA
Legal namestring
(주)바이오포아
Websiteurl
biopoa.co.kr
Company typeenum
Private
Founded yearint
2007
Descriptiontext

BIOPOA (주식회사 바이오포아) is a South Korean veterinary biopharmaceutical company founded in February 2007 by CEO Cho Sun-hee, specializing in animal vaccine development based on proprietary reverse genetics (역유전학) platform technology. The company's core innovation is SAVE (Synthetic Attenuated Virus Engineering) — the world's first reverse genetics platform applied to PRRS (Porcine Reproductive and Respiratory Syndrome) vaccine manufacturing — combined with Codon Pair Deoptimization (CPD) to control pathogenicity without amino acid modification while maintaining strong immune response. The commercial portfolio centers on two PoaVac-branded live vaccines: PoaVac PRRS (launched April 2021, the first domestically developed Korean PRRS live vaccine using locally isolated North American-type strains) and PoaVac Gumboro/IBD (approved August 2025 for poultry), with a sow-specific PRRS variant added in February 2025.

The business model operates through three revenue streams: direct B2B vaccine product sales, technology licensing and royalties, and contract research services. Domestically, products are sold exclusively through Korea SomeBeth (한국썸벧), a Harim Group subsidiary that is also an equity investor. Internationally, BIOPOA operates a technology transfer model with global animal pharmaceutical company CEVA (France), which handles product registration and distribution across Cambodia, Thailand, Mexico, and Vietnam. Manufacturing occurs at KVGMP-certified facilities in Hwaseong-si, Gyeonggi-do, with both egg-based (2020) and cell culture-based (2021) GMP approvals.

The company has received multiple certifications validating its technology platform: NeT (New Technology) certification from the Ministry of Agriculture for SAVE technology (2022), INNO Biz AA grade (2022), and NICE D&B preliminary technology assessment A grade (2022). Government recognition in 2025 included the Green Bio Best Award from the Minister of Agriculture and the Animal Drug Self-Inspection Best Company award from the Animal and Plant Quarantine Agency. BIOPOA completed a pre-IPO funding round in July 2024 at a reported 560 billion KRW (~$400M) enterprise value, with investors including Meta Investment, L&S Venture Investment, Korea Somevet, and CEVA, signaling preparation for a public listing.

Short descriptiontext

BIOPOA is a South Korean veterinary biopharmaceutical company that develops animal vaccines using proprietary reverse genetics SAVE technology, primarily for PRRS in pigs and Gumboro disease in poultry, distributing domestically through Korea SomeBeth and internationally via technology transfer partner CEVA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersJangan, South Korea
HQ citystring
Jangan
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
animal vaccine development, reverse genetics technology, porcine respiratory vaccines, veterinary pharmaceuticals, live attenuated vaccines
Industry5 codes
PRIMARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
SECONDARYHLAMAKAC
Poultry Vaccines
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Veterinary Pharmaceuticals (Animal Vaccines)
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Product Sales
TypeOne Time License
Description

Direct sales of animal vaccines including PRRS live vaccine (포아백 PRRS 생백신) and Gumboro live vaccine (포아백 감보로 생백신) to pig and poultry farms through domestic distributor Korea SomeBeth and international channels.

biopoa.co.kr
2Technology Licensing
TypeLicensing Royalties
Description

Technology transfer agreements with global animal pharmaceutical companies. Initial technology contract payment received from CEVA in December 2022 for PRRS vaccine technology. Joint vaccine strain development and manufacturing technology cooperation with CEVA for European markets.

biopoa.co.kr
3Contract Research Services
TypeProfessional Services
Description

Self-testing commissioned work for multinational animal pharmaceutical companies, providing laboratory testing and validation services.

biopoa.co.kr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1포아백 PRRS 생백신 - 100ml (50 pig dose)
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Product sold in 100ml bottles (50 pig dose basis) through distribution partners

biopoa.co.kr
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1포아백(PoaVac)
Description

Vaccine product brand under BioPoa, including '포아백 PRRS 생백신' (PRRS live vaccine) and '포아백 감보로 생백신' (Gumboro live vaccine). Marketed through distribution partner Hansome벧 (한국썸벧).

biopoa.co.kr
+1 more record
Core offering1 text field

BIOPOA develops and manufactures animal vaccines using proprietary reverse genetics SAVE (Synthetic Attenuated Virus Engineering) technology. Its core product is the PoaVac PRRS Live Vaccine (포아백 PRRS 생백신) for porcine reproductive and respiratory syndrome, supplemented by the PoaVac Gumboro Live Vaccine (포아백 감보로 생백신) for poultry infectious bursal disease. Products are sold to commercial pig and poultry farms through exclusive Korean distributor Korea SomeBeth and international technology partner CEVA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99%+ virus inhibition in vaccinated pigs compared to control group
+3 more records
Product overview1 text field

BIOPOA is a veterinary pharmaceutical company specializing in animal vaccines developed using proprietary reverse genetics (역유전학) technology. The core product portfolio centers on two main vaccine brands: 포아백 PRRS 생백신 (PoaVac PRRS Live Vaccine) for Porcine Reproductive and Respiratory Syndrome in pigs, and 포아백 감보로 생백신 (PoaVac Gumboro Live Vaccine) for Infectious Bursal Disease in poultry. The company also produced the PoaCheck COVID-19 diagnostic kit. All vaccines leverage the innovative SAVE (Synthetic Attenuated Virus Engineering) platform for superior safety and immunogenicity. Products are manufactured in KVGMP-certified facilities and distributed domestically through Korea Somvet (한국썸벧), with international distribution via technology transfer partner CEVA to markets including Cambodia, Thailand, Mexico, and Vietnam.

Product and service5 records
1PoaVac PRRS Live Vaccine (포아백 PRRS 생백신)
CategoryVeterinary Vaccines - Porcine
Description

World's first PRRS (Porcine Reproductive and Respiratory Syndrome) live vaccine developed using reverse genetics SAVE technology. Combines two North American-type PRRS virus strains from domestic isolates for broad cross-immunity, uses codon pair deoptimization to control pathogenicity while maintaining immunogenicity, prevents farm-to-farm circulation, and reduces reversion risk. Sold in 100ml bottles (50 pig dose basis).

2PoaVac PRRS Live Vaccine for Sows (포아백 PRRS 생백신 모돈용)
CategoryVeterinary Vaccines - Porcine
Description

Sow-specific variant of the PoaVac PRRS Live Vaccine targeting high-pathogenicity PRRS control in breeding pigs and sows, addressing reproductive failure prevention.

3PoaVac Gumboro Live Vaccine (포아백 감보로 생백신)
CategoryVeterinary Vaccines - Poultry
Description

Live vaccine for chicken Infectious Bursal Disease (IBD/Gumboro disease) using domestically circulating intermediate-toxin IBDV strain with reverse genetics technology to overcome maternal-derived antibodies (MDA), targeting variant strains (G2d, G2b) prevalent in Korea.

4PoaCheck COVID-19 Diagnostic Kit
CategoryIn Vitro Diagnostics
Description

In vitro diagnostic kit for COVID-19 detection. Received CE certification and export approval August 2020 with first overseas export to Uzbekistan in January 2021.

5Contract Research and Laboratory Testing Services
CategoryContract Research Services
Description

Self-testing commissioned work and laboratory testing and validation services provided to multinational animal pharmaceutical companies, leveraging designation as an animal drug testing institution and livestock disease diagnostic institution.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

MOU signed for joint development of poultry disease platform vaccines targeting avian influenza (AI), infectious bronchitis (IB), and Newcastle disease (ND). Collaboration aims to enhance field-based vaccine development using farm data and establish rapid response system for livestock diseases. Joint clinical evaluation and commercialization planned by 2026.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-10-01
Description

Technology transfer agreement for 포아백 PRRS 생백신 to global animal pharmaceutical company CEVA (headquartered in France). Initial contract payment received December 2022. CEVA handling product registration and distribution in international markets including Cambodia, Thailand, Mexico, and Vietnam. Joint development of European-adapted vaccine strains and manufacturing technology cooperation.

3Korea SomeBeth (한국썸벧)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Domestic distribution partnership for 포아백 PRRS 생백신 and other vaccines. SomeBeth handles domestic sales to pig and poultry farms. Investment from Harim Group subsidiary SomeBeth received in December 2020.

biopoa.co.kr
4Animal and Plant Quarantine Agency (농림축산검역본부)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint research partnership for PRRS vaccine development since 2016. Collaborative development of 포아백 PRRS 생백신 - jointly developed with quarantine agency. Cooperative research for product registration and export certification.

biopoa.co.kr
5Seoul National University Agriculture and Life Sciences Venture Center (서울대 농업생명대학 창업 보육센터)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Business incubation support received during early company stage - admitted to startup incubator in September 2005.

biopoa.co.kr
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Largest pure-play animal health company globally with a broad swine and poultry vaccine portfolio including competitor products. Comparable as the scale benchmark BIOPOA must meet to win enterprise accounts and tenders.

TypeBroad incumbent
Description

Animal health company with a swine vaccine portfolio including PRRS-related products. Comparable as a mid-to-large animal health competitor with similar species focus but broader global footprint than BIOPOA.

TypeDirect peer
Description

Spanish animal health company specializing in vaccines and diagnostics for swine and poultry, with comparable product categories to BIOPOA (PRRS, Gumboro). Direct mid-sized specialist competitor that mirrors BIOPOA's niche-led, technology-focused business model.

TypeDirect peer
Description

Global animal health company headquartered in France and BIOPOA's technology transfer and equity partner for PRRS vaccines. Directly competes in veterinary vaccines across swine and poultry, making it both a partner and the most direct competitive comparable for BIOPOA's commercial model.

TypeDirect peer
Description

Korean animal vaccine and pharmaceutical manufacturer with overlapping product categories in veterinary biologicals. Direct domestic comparable in the Korean animal vaccine market where BIOPOA competes for share and distribution partnerships.

TypeBroad incumbent
Description

Major multinational animal health competitor with PRRS vaccine offerings (e.g., PRIME PAC PRRS) and integrated global manufacturing and distribution. Comparable as an established incumbent that BIOPOA competes against in international tenders.

TypeDirect peer
Description

Korean veterinary vaccine manufacturer with comparable product portfolio in livestock and poultry vaccines. Direct domestic peer competing for the same Korean animal health accounts and government vaccine programs.

8Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

One of the largest global animal health companies and incumbent leader in PRRS vaccines via Ingelvac PRRS. Comparable as the dominant multinational competitor BIOPOA is attempting to displace in domestic Korean and regional Asian markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BIOPOA

Veterinary Pharmaceuticals (Animal Vaccines)biopoa.co.kr

BIOPOA is a South Korean veterinary biopharmaceutical company that develops animal vaccines using proprietary reverse genetics SAVE technology, primarily for PRRS in pigs and Gumboro disease in poultry, distributing domestically through Korea SomeBeth and internationally via technology transfer partner CEVA.

What BIOPOA does

BIOPOA (주식회사 바이오포아) is a South Korean veterinary biopharmaceutical company founded in February 2007 by CEO Cho Sun-hee, specializing in animal vaccine development based on proprietary reverse genetics (역유전학) platform technology. The company's core innovation is SAVE (Synthetic Attenuated Virus Engineering) — the world's first reverse genetics platform applied to PRRS (Porcine Reproductive and Respiratory Syndrome) vaccine manufacturing — combined with Codon Pair Deoptimization (CPD) to control pathogenicity without amino acid modification while maintaining strong immune response. The commercial portfolio centers on two PoaVac-branded live vaccines: PoaVac PRRS (launched April 2021, the first domestically developed Korean PRRS live vaccine using locally isolated North American-type strains) and PoaVac Gumboro/IBD (approved August 2025 for poultry), with a sow-specific PRRS variant added in February 2025.

The business model operates through three revenue streams: direct B2B vaccine product sales, technology licensing and royalties, and contract research services. Domestically, products are sold exclusively through Korea SomeBeth (한국썸벧), a Harim Group subsidiary that is also an equity investor. Internationally, BIOPOA operates a technology transfer model with global animal pharmaceutical company CEVA (France), which handles product registration and distribution across Cambodia, Thailand, Mexico, and Vietnam. Manufacturing occurs at KVGMP-certified facilities in Hwaseong-si, Gyeonggi-do, with both egg-based (2020) and cell culture-based (2021) GMP approvals.

The company has received multiple certifications validating its technology platform: NeT (New Technology) certification from the Ministry of Agriculture for SAVE technology (2022), INNO Biz AA grade (2022), and NICE D&B preliminary technology assessment A grade (2022). Government recognition in 2025 included the Green Bio Best Award from the Minister of Agriculture and the Animal Drug Self-Inspection Best Company award from the Animal and Plant Quarantine Agency. BIOPOA completed a pre-IPO funding round in July 2024 at a reported 560 billion KRW (~$400M) enterprise value, with investors including Meta Investment, L&S Venture Investment, Korea Somevet, and CEVA, signaling preparation for a public listing.

BIOPOA firmographics

Firmographics
Name
BIOPOA
Legal name
(주)바이오포아
Website
https://biopoa.co.kr
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
BIOPOA is a South Korean veterinary biopharmaceutical company that develops animal vaccines using proprietary reverse genetics SAVE technology, primarily for PRRS in pigs and Gumboro disease in poultry, distributing domestically through Korea SomeBeth and internationally via technology transfer partner CEVA.
Ownership category
akta.pro rank

BIOPOA industry classification

Industry
Product category
Veterinary Pharmaceuticals (Animal Vaccines)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
SECONDARYHLAMAKAC
Poultry Vaccines
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs

Keywords

  • Animal vaccine development
  • Reverse genetics technology
  • Porcine respiratory vaccines
  • Veterinary pharmaceuticals
  • Live attenuated vaccines

Where BIOPOA is headquartered

Location

Headquarters

HQ city
Jangan
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

BIOPOA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Vaccine Product Sales: Direct sales of animal vaccines including PRRS live vaccine (포아백 PRRS 생백신) and Gumboro live vaccine (포아백 감보로 생백신) to pig and poultry farms through domestic distributor Korea SomeBeth and international channels.
  2. Technology Licensing: Technology transfer agreements with global animal pharmaceutical companies. Initial technology contract payment received from CEVA in December 2022 for PRRS vaccine technology. Joint vaccine strain development and manufacturing technology cooperation with CEVA for European markets.
  3. Contract Research Services: Self-testing commissioned work for multinational animal pharmaceutical companies, providing laboratory testing and validation services.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contract포아백 PRRS 생백신 - 100ml (50 pig dose)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

BIOPOA product offering

Product offering

Core offering

BIOPOA develops and manufactures animal vaccines using proprietary reverse genetics SAVE (Synthetic Attenuated Virus Engineering) technology. Its core product is the PoaVac PRRS Live Vaccine (포아백 PRRS 생백신) for porcine reproductive and respiratory syndrome, supplemented by the PoaVac Gumboro Live Vaccine (포아백 감보로 생백신) for poultry infectious bursal disease. Products are sold to commercial pig and poultry farms through exclusive Korean distributor Korea SomeBeth and international technology partner CEVA.

Product overview

BIOPOA is a veterinary pharmaceutical company specializing in animal vaccines developed using proprietary reverse genetics (역유전학) technology. The core product portfolio centers on two main vaccine brands: 포아백 PRRS 생백신 (PoaVac PRRS Live Vaccine) for Porcine Reproductive and Respiratory Syndrome in pigs, and 포아백 감보로 생백신 (PoaVac Gumboro Live Vaccine) for Infectious Bursal Disease in poultry. The company also produced the PoaCheck COVID-19 diagnostic kit. All vaccines leverage the innovative SAVE (Synthetic Attenuated Virus Engineering) platform for superior safety and immunogenicity. Products are manufactured in KVGMP-certified facilities and distributed domestically through Korea Somvet (한국썸벧), with international distribution via technology transfer partner CEVA to markets including Cambodia, Thailand, Mexico, and Vietnam.

Differentiator

Problem solved

Functional benefit

Brands

  • 포아백(PoaVac): Vaccine product brand under BioPoa, including '포아백 PRRS 생백신' (PRRS live vaccine) and '포아백 감보로 생백신' (Gumboro live vaccine). Marketed through distribution partner Hansome벧 (한국썸벧).
  • PoaCheck

Products and services

  • PoaVac PRRS Live Vaccine (포아백 PRRS 생백신) World's first PRRS (Porcine Reproductive and Respiratory Syndrome) live vaccine developed using reverse genetics SAVE technology. Combines two North American-type PRRS virus strains from domestic isolates for broad cross-immunity, uses codon pair deoptimization to control pathogenicity while maintaining immunogenicity, prevents farm-to-farm circulation, and reduces reversion risk. Sold in 100ml bottles (50 pig dose basis).
  • PoaVac PRRS Live Vaccine for Sows (포아백 PRRS 생백신 모돈용) Sow-specific variant of the PoaVac PRRS Live Vaccine targeting high-pathogenicity PRRS control in breeding pigs and sows, addressing reproductive failure prevention.
  • PoaVac Gumboro Live Vaccine (포아백 감보로 생백신) Live vaccine for chicken Infectious Bursal Disease (IBD/Gumboro disease) using domestically circulating intermediate-toxin IBDV strain with reverse genetics technology to overcome maternal-derived antibodies (MDA), targeting variant strains (G2d, G2b) prevalent in Korea.
  • PoaCheck COVID-19 Diagnostic Kit In vitro diagnostic kit for COVID-19 detection. Received CE certification and export approval August 2020 with first overseas export to Uzbekistan in January 2021.
  • Contract Research and Laboratory Testing Services Self-testing commissioned work and laboratory testing and validation services provided to multinational animal pharmaceutical companies, leveraging designation as an animal drug testing institution and livestock disease diagnostic institution.

Quantifiable outcome

  • 99%+ virus inhibition in vaccinated pigs compared to control group
  • +3 more outcomes

Companies that use BIOPOA

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

BIOPOA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BIOPOA partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Harim (하림)coreStrategic or Co-development Partner · 2 April 2026MOU signed for joint development of poultry disease platform vaccines targeting avian influenza (AI), infectious bronchitis (IB), and Newcastle disease (ND). Collaboration aims to enhance field-based vaccine development using farm data and establish rapid response system for livestock diseases. Joint clinical evaluation and commercialization planned by 2026.
  • CEVAcoreOEM/ Whitelabel/ Licensing Partner · 1 October 2022Technology transfer agreement for 포아백 PRRS 생백신 to global animal pharmaceutical company CEVA (headquartered in France). Initial contract payment received December 2022. CEVA handling product registration and distribution in international markets including Cambodia, Thailand, Mexico, and Vietnam. Joint development of European-adapted vaccine strains and manufacturing technology cooperation.
  • Korea SomeBeth (한국썸벧)coreChannel Partner/ Reseller/ DistributorDomestic distribution partnership for 포아백 PRRS 생백신 and other vaccines. SomeBeth handles domestic sales to pig and poultry farms. Investment from Harim Group subsidiary SomeBeth received in December 2020.
  • Animal and Plant Quarantine Agency (농림축산검역본부)coreStrategic or Co-development PartnerJoint research partnership for PRRS vaccine development since 2016. Collaborative development of 포아백 PRRS 생백신 - jointly developed with quarantine agency. Cooperative research for product registration and export certification.
  • Seoul National University Agriculture and Life Sciences Venture Center (서울대 농업생명대학 창업 보육센터)minorStrategic or Co-development PartnerBusiness incubation support received during early company stage - admitted to startup incubator in September 2005.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

BIOPOA competitors and assessment

Company assessment

Broad incumbents

  • Zoetis: Largest pure-play animal health company globally with a broad swine and poultry vaccine portfolio including competitor products. Comparable as the scale benchmark BIOPOA must meet to win enterprise accounts and tenders.
  • Phibro Animal Health: Animal health company with a swine vaccine portfolio including PRRS-related products. Comparable as a mid-to-large animal health competitor with similar species focus but broader global footprint than BIOPOA.
  • Merck Animal Health: Major multinational animal health competitor with PRRS vaccine offerings (e.g., PRIME PAC PRRS) and integrated global manufacturing and distribution. Comparable as an established incumbent that BIOPOA competes against in international tenders.
  • Boehringer Ingelheim Animal Health: One of the largest global animal health companies and incumbent leader in PRRS vaccines via Ingelvac PRRS. Comparable as the dominant multinational competitor BIOPOA is attempting to displace in domestic Korean and regional Asian markets.

Direct peers

  • HIPRA: Spanish animal health company specializing in vaccines and diagnostics for swine and poultry, with comparable product categories to BIOPOA (PRRS, Gumboro). Direct mid-sized specialist competitor that mirrors BIOPOA's niche-led, technology-focused business model.
  • Ceva Santé Animale: Global animal health company headquartered in France and BIOPOA's technology transfer and equity partner for PRRS vaccines. Directly competes in veterinary vaccines across swine and poultry, making it both a partner and the most direct competitive comparable for BIOPOA's commercial model.
  • Komipharm International: Korean animal vaccine and pharmaceutical manufacturer with overlapping product categories in veterinary biologicals. Direct domestic comparable in the Korean animal vaccine market where BIOPOA competes for share and distribution partnerships.
  • Choong Ang Vaccine Laboratories (CAVC): Korean veterinary vaccine manufacturer with comparable product portfolio in livestock and poultry vaccines. Direct domestic peer competing for the same Korean animal health accounts and government vaccine programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

BIOPOA compliance and trust

Trust signal

Compliance5 records

BIOPOA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BIOPOA leadership team

Management profile

Number of profiles

Profiles1 record

BIOPOA funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BIOPOA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOPOA

What does BIOPOA do?

BIOPOA develops and manufactures animal vaccines using proprietary reverse genetics SAVE (Synthetic Attenuated Virus Engineering) technology. Its core product is the PoaVac PRRS Live Vaccine (포아백 PRRS 생백신) for porcine reproductive and respiratory syndrome, supplemented by the PoaVac Gumboro Live Vaccine (포아백 감보로 생백신) for poultry infectious bursal disease. Products are sold to commercial pig and poultry farms through exclusive Korean distributor Korea SomeBeth and international technology partner CEVA.

Is BIOPOA a public or private company?

BIOPOA is a private company. It is classified as venture growth investor backed and is currently operating.

When was BIOPOA founded?

BIOPOA was founded in 2007. It employs 51 to 100 people.

Where is BIOPOA based?

BIOPOA is headquartered in Jangan, South Korea, in the Asia region.

How does BIOPOA make money?

Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are technology Licensing and contract Research Services.

Who are BIOPOA's main competitors?

Broad incumbents on record are Zoetis, Phibro Animal Health, Merck Animal Health and Boehringer Ingelheim Animal Health. Direct peers are HIPRA, Ceva Santé Animale, Komipharm International and Choong Ang Vaccine Laboratories (CAVC).

Does BIOPOA have an API?

No public API is recorded for BIOPOA.

What industry is BIOPOA in?

BIOPOA's product category is Veterinary Pharmaceuticals (Animal Vaccines). Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
스타트업엔(StartupN)Harim-BioPoa, joint development of 'poultry disease vaccine'... full-scale response to avian influenzaHarim, a South Korean comprehensive food company, has partnered with animal vaccine technology company BioPoa to jointly develop next-generation poultry disease platform vaccines targeting Avian Influenza, Infectious Bronchitis, Newcastle Disease, and Infectious Bursal Disease. The MOU was signed at Harim's headquarters in Iksan, Jeollabuk-do, establishing a five-year strategic collaboration leveraging Harim's large-scale breeding infrastructure and farm data combined with BioPoa's vaccine technology. The partnership aims to conduct field-based vaccine development with outdoor clinical evaluations beginning in 2026, positioning both companies to potentially enter the global animal vaccine market while strengthening domestic livestock biosecurity.ZdnetBioPoa successfully completed its pre-IPO investment attraction.BioPoa announced on the 12th that it has completed its pre-IPO investment attraction, including funds from Harim's subsidiary Korea Sunbet, Ceva Sante Animal, Meta Investment and L&S Venture Capital. The reverse-genetics-based PRRS vaccine, launched in 2021, holds a 10% domestic market share and is seeking export permits in Southeast Asia and South America. The company also plans sequential domestic approvals for other viral vaccines.PharmnewsBioPoa successfully completed its pre-IPO investment attraction.BioPoa, established in 2007, has received matching investment from Korea's High-Tech Technology Development Commercialization Fund of Korea Venture Investment and been selected for a 1.5 billion won scale-up TIPS research project. The company is developing a new version of the PRRS live vaccine in collaboration with the National Animal Quarantine Agency to address the emerging PRRSV variant.